Biomea Fusion (NASDAQ: BMEA)
$3.98
(-6.8%)
-$0.29
Price as of January 10, 2025, 4:00 p.m. ET
Biomea Fusion Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biomea Fusion Company Info
Biomea Fusion, Inc. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
News & Analysis
Featured Article
Why Biomea Fusion Stock Crushed It This Week
A promising data readout in type 2 diabetes lit a fire underneath the biotech's stock this week.
George Budwell | Mar 30, 2023
Featured Article
Why Shares of Biomea Fusion Jumped This Week
The company launched its second trial this year on its lead therapy.
Jim Halley | Jan 20, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.